-
公开(公告)号：US11701373B2
公开(公告)日：2023-07-18
申请号：US17307138
申请日：2021-05-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , T. G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC: A61K31/695 , C07F7/08 , A61K31/135 , C07D215/14 , C07D241/04 , C07C323/29 , C07C251/38 , C07C251/42 , C07C251/44 , C07D209/46 , C07D213/38 , C07C275/26 , C07C217/74 , C07C323/25 , C07C235/46 , C07F9/54 , C07F9/572 , C07F9/09 , C07C215/42 , C07C217/52 , C07C217/58 , C07C219/24 , C07C233/41 , C07C233/65 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07D213/32 , C07D213/69 , C07D213/70 , C07D215/12 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F9/117 , C07F9/62 , C07F9/6503 , C07F9/6509 , C07F9/655 , C07F9/6553 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661
CPC classification number: A61K31/695 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661 , C07C215/42 , C07C217/52 , C07C217/58 , C07C217/74 , C07C219/24 , C07C233/41 , C07C233/65 , C07C235/46 , C07C251/38 , C07C251/42 , C07C251/44 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C275/26 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07C323/25 , C07C323/29 , C07D209/46 , C07D213/32 , C07D213/38 , C07D213/69 , C07D213/70 , C07D215/12 , C07D215/14 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/04 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F7/08 , C07F7/081 , C07F9/091 , C07F9/117 , C07F9/5442 , C07F9/5728 , C07F9/62 , C07F9/65031 , C07F9/65522 , C07F9/650952 , C07F9/655345 , C07B2200/05 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/10 , C07C2603/74
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):
and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.-
12.发明授权公开(公告)号：US11597721B2
公开(公告)日：2023-03-07
申请号：US16982937
申请日：2019-03-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zili Xiao , Michael G. Yang , Chunjian C. Liu , Trevor C. Sherwood , John L. Gilmore , David S. Weinstein
IPC: C07D401/14 , C07D413/14 , C07D417/14 , C07D513/04
Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US20230020273A1
公开(公告)日：2023-01-19
申请号：US17289269
申请日：2019-10-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Steven H. Spergel , William J. Pitts , Michael E. Mertzman , Ryan M. Moslin , Trevor C. Sherwood , John L. Gilmore , Alaric J. Dyckman
IPC: C07D413/14 , C07B59/00 , C07D403/12 , C07D413/12 , C07D417/14 , C07D417/12 , C07D401/14 , C07D403/14
Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US10709719B2
公开(公告)日：2020-07-14
申请号：US16188444
申请日：2018-11-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , T. G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC: A61K31/695 , C07F7/08 , A61K31/135 , C07D215/14 , C07D241/04 , C07C323/29 , C07C251/38 , C07C251/42 , C07C251/44 , C07D209/46 , C07D213/38 , C07C275/26 , C07C217/74 , C07C323/25 , C07C235/46 , C07F9/54 , C07F9/572 , C07F9/09 , C07C215/42 , C07C217/52 , C07C217/58 , C07C219/24 , C07C233/41 , C07C233/65 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07D213/32 , C07D213/69 , C07D213/70 , C07D215/12 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F9/117 , C07F9/62 , C07F9/6503 , C07F9/6509 , C07F9/655 , C07F9/6553 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
公开(公告)号：US20170042917A1
公开(公告)日：2017-02-16
申请号：US15337843
申请日：2016-10-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , T.G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC: A61K31/695 , A61K31/351 , A61K31/415 , A61K31/381 , A61K31/44 , A61K31/137 , A61K31/166 , A61K31/4406 , A61K31/4409 , A61K31/4402 , A61K31/4965 , A61K31/165 , A61K31/4174 , A61K31/426 , A61K31/337 , A61K31/47 , A61K31/505 , A61K31/27 , A61K31/17 , A61K31/352 , A61K31/15 , A61K31/661 , A61K31/222 , A61K31/24 , A61K31/135
CPC classification number: A61K31/695 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661 , C07B2200/05 , C07C215/42 , C07C217/52 , C07C217/58 , C07C217/74 , C07C219/24 , C07C233/41 , C07C233/65 , C07C235/46 , C07C251/38 , C07C251/42 , C07C251/44 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C275/26 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07C323/25 , C07C323/29 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/10 , C07C2603/74 , C07D209/46 , C07D213/32 , C07D213/38 , C07D213/69 , C07D213/70 , C07D215/12 , C07D215/14 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/04 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F7/081 , C07F9/091 , C07F9/117 , C07F9/5442 , C07F9/5728 , C07F9/62 , C07F9/65031 , C07F9/650952 , C07F9/65522 , C07F9/655345
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Abstract translation: 和/或其盐，其中R1是-OH或-OP（O）（OH）2，X1，X2，X3，R2，R2a，Ra，Rb和Rc在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫疾病和血管疾病）中的疾病或病症的进展。
-
Patent Agency Ranking
公开(公告)号：US11820768B2
公开(公告)日：2023-11-21
申请号：US17245595
申请日：2021-04-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , Dharmpal S. Dodd , Christopher P. Mussari , Trevor C. Sherwood , Brian K. Whiteley , John L. Gilmore , Sreekantha Ratna Kumar , Laxman Pasunoori , Pitani Veera Venkata Srinivas , Srinivasan Kunchithapatham Duraisamy , Subramanya Hegde , Rushith Kumar Anumula
IPC: C07D471/04 , A61K31/437 , C07D491/107 , C07D471/08 , A61P25/00 , A61P29/00 , A61P19/02 , C07D495/10 , C07D519/00 , A61P37/00
CPC classification number: C07D471/04 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/00 , C07D471/08 , C07D491/107 , C07D495/10 , C07D519/00
Abstract: Disclosed are compounds of Formula (I)
N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.-
公开(公告)号：US11053244B1
公开(公告)日：2021-07-06
申请号：US16910101
申请日：2020-06-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , Dharmpal S. Dodd , Christopher P. Mussari , Trevor C. Sherwood , Brian K. Whiteley , John L. Gilmore , Sreekantha Ratna Kumar , Laxman Pasunoori , Pitani Veera Venkata Srinivas , Srinivasan Kunchithapatham Duraisamy , Subramanya Hegde , Rushith Kumar Anumula
IPC: C07D471/04 , A61K31/437 , C07D491/107 , C07D471/08 , A61P25/00 , A61P37/00 , A61P19/02 , C07D495/10 , C07D519/00 , A61P29/00
Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
-
公开(公告)号：US20210147357A1
公开(公告)日：2021-05-20
申请号：US16636670
申请日：2018-08-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , Ling Li , John L. Gilmore
IPC: C07D207/16
Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH2— or —C(O)—; R1 is —OH or —OP(O)(OH)2; L is a bond, —CH2—, or —C(O)—; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and —CH3; and n is zero, 1, or 2; provided that if X is —CH2—, then L is —CH2— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor SlP1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
19.发明申请公开(公告)号：US20210032220A1
公开(公告)日：2021-02-04
申请号：US16982937
申请日：2019-03-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zili Xiao , Michael G. Yang , Chunjian C. Liu , Trevor C. Sherwood , John L. Gilmore , David S. Weinstein
IPC: C07D401/14 , C07D417/14 , C07D513/04 , C07D413/14
Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US10730877B2
公开(公告)日：2020-08-04
申请号：US16695303
申请日：2019-11-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , Dharmpal S. Dodd , Christopher P. Mussari , Trevor C. Sherwood , Brian K. Whiteley , John L. Gilmore , Sreekantha Ratna Kumar , Laxman Pasunoori , Pitani Veera Venkata Srinivas , Srinivasan Kunchithapatham Duraisamy , Subramanya Hegde , Rushith Kumar Anumula
IPC: C07D471/04 , A61K31/437 , C07D491/107 , C07D471/08 , A61P25/00 , A61P37/00 , A61P19/02 , C07D495/10 , C07D519/00 , A61P29/00
Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.023 seconds)
